VIVEbiotech is a Company with a very wide expertise in Lentiviral vectors, having been focused on it during the last years,

The 26th of May, Juan Carlos Ramirez (Scientific Director), gave an oral presentation in the Conference organized by Fundación Victor Grifols I Lucas entitled “CRISPR… Does Genetic revolution have limit?”.

VIVEtech´s team composed by César Trigueros (GMP Development Director), Juan Carlos Ramirez (Chief Technology/Scientific Officer) and Natalia Elizalde (Business Development Director) attended ASGCT event hold from May 10^th to May 13^th at Washington.

The European Commission has awarded VIVEbiotech the Seal of Excellence for the development of Lentisoma, an innovative safe vehicle for genes that serve as medicines.

The biotechnology company VIVEbiotech and the delegation of the Basque Country of the Spanish Federation of Rare Diseases (Federación Española de Enfermedades Raras, FEDER) have signed a collaboration agreement that will allow people suffering from a rare disease in the Basque Country to receive a quality, comprehensive and specialized support.

What are viral vectors? What are they used for? Juan Carlos Ramírez, the Scientific Director of VIVEbiotech, clarifies these doubts about viral vectors, the “vehicles” in which VIVEbiotech works, the ones that could be used to cure monogenic diseases in the future.